Chimeric antigen receptor–T cell (CAR-T) therapy has transformed the management of refractory hematological malignancies. Now that targeting pathogenic cells of interest with antigen-directed cytotoxic T lymphocytes is possible, the field is expanding the reach of CAR-T therapy beyond oncology. Recently, breakthrough progress has been made in the application of CAR-T technology to autoimmune diseases, exploiting the same validated targets that were used by pioneering CAR-T therapies in hematology. Here, we discuss recent advances and outcomes that are paving the way for extension to new therapeutic areas, including autoimmunity.

中文翻译：

---

针对自身免疫性疾病及其他疾病的 CAR-T 疗法的工程化


嵌合抗原受体-T 细胞 （CAR-T） 疗法改变了难治性血液系统恶性肿瘤的管理。既然可以用抗原定向的细胞毒性 T 淋巴细胞靶向感兴趣的致病细胞，该领域正在将 CAR-T 疗法的范围扩展到肿瘤学之外。最近，CAR-T 技术在自身免疫性疾病中的应用取得了突破性进展，利用了与血液学领域开创性 CAR-T 疗法相同的经过验证的靶点。在这里，我们讨论了为扩展到新的治疗领域（包括自身免疫）铺平道路的最新进展和结果。